Prostate Cancer Reports
54

Volume 5 Supplement 9
September 2017



Home > Prostate Cancer Reports > Volume 5, Year 2017 > Supplement 9, September


CONTENTS



INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT





INTEGRATIVE MEDICINE



Raval AD, Thakker D, Negi H, Vyas A, Kaur H, Salkini MW.
Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.
Prostate Cancer Prostatic Dis. 2016 Jun;19(2):151-62. doi: 10.1038/pcan.2015.58. Epub 2016 Jan 19.
Erratum in: Prostate Cancer Prostatic Dis. 2016 Jun;19(2):222. Kaur, H [added].
Source | Abstract | Full text | Similar articles





OVERALL MANAGEMENT



Barra S, Gion M, Introini C, Neumaier C, Sambuceti G, Simonato A, Spina B, Tomasello L
Linee guida. Carcinoma della prostata. Edizione 2016
Associazione Italiana di Oncologia Medica (AIOM).
http://www.aiom.it. (Italian)
Source | Abstract | Full text | Similar articles




Alitto A, Filippo Alongi F, Antognoni P, Arcangeli S, Augurio A, Bellavita R, Bertoni F, Bonetta A, Borghesi S, Bruni A, Buglione M, Cagna E, Cazzaniga LF, Corvò R, D’Agostino G, D’Amico R, D’Angelillo RM, Detti B, De Renzi F, Fabrini MG, Fersino S, Frascino V. et al.
Linee guida Carcinoma della Prostata - AIRO, 2016
Tumori 2016; Special Issue 1: S1-S79. DOI: 10.5301/TJ.2016.15934
. Epub 2016 Jun 23. (Italian)
Source | Abstract | Full text | Similar articles





PROGNOSIS



Alkhateeb S, Alibhai S, Fleshner N, Finelli A, Jewett M, Zlotta A, Nesbitt M, Lockwood G, Trachtenberg J.
Impact of positive surgical margins after radical prostatectomy differs by disease risk group.
J Urol. 2010 Jan;183(1):145-50. doi: 10.1016/j.juro.2009.08.132. Epub 2009 Nov 13.
Source | Abstract | Full text | Similar articles




Chan TY, Partin AW, Walsh PC, Epstein JI.
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.
Urology. 2000 Nov 1;56(5):823-7.
Source | Abstract | Full text | Similar articles




Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL.
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?
Urology. 2016 Jan;87:125-32. doi: 10.1016/j.urology.2015.08.026. Epub 2015 Sep 21.
Source | Abstract | Full text | Similar articles




Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB.
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
J Urol. 1998 Dec;160(6 Pt 2):2407-11.
Source | Abstract | Full text | Similar articles




Gandaglia G, Schiffmann J, Schlomm T, Fossati N, Moschini M, Suardi N, Chun FK, Montorsi F, Graefen M, Briganti A.
Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.
Prostate. 2015 Sep;75(13):1484-91. doi: 10.1002/pros.23040. Epub 2015 Jul 14.
Source | Abstract | Full text | Similar articles




Hong SK, Vertosick E, Sjoberg DD, Scardino PT, Eastham JA.
Insignificant disease among men with intermediate-risk prostate cancer.
World J Urol. 2014 Dec;32(6):1417-21. doi: 10.1007/s00345-014-1413-3. Epub 2014 Sep 27.
Source | Abstract | Full text | Similar articles




Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J, Deng FM.
Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.
Am J Surg Pathol. 2014 Aug;38(8):1096-101. doi: 10.1097/PAS.0000000000000235. Epub 2014 Aug 1.
Source | Abstract | Full text | Similar articles




Jung JW, Lee JK, Hong SK, Byun SS, Lee SE.
Stratification of patients with intermediate-risk prostate cancer.
BJU Int. 2015 Jun;115(6):907-12. doi: 10.1111/bju.12703. Epub 2015 Mar 27.
Source | Abstract | Full text | Similar articles




Kane CJ, Eggener SE, Shindel AW, Andriole GL.
Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.
Eur Urol Focus. 2017 Mar 12. pii: S2405-4569(16)30157-2. doi: 10.1016/j.euf.2016.10.010. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ.
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Cancer. 2015 May 1;121(9):1414-21. doi: 10.1002/cncr.29147. Epub 2014 Dec 9.
Source | Abstract | Full text | Similar articles | Meeting abstract (2015 May 17) | Meeting abstract (2014 Feb) | Meeting abstract (2012 Feb)




Mearini L.
Editorial Comment to Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Int J Urol. 2015 Nov;22(11):1035-6. doi: 10.1111/iju.12904. Epub 2015 Aug 25.
Source | Abstract | Full text | Similar articles




Mihalcik SA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.
Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT.
Eur Urol Focus. 2016 Mar 3. pii: S2405-4569(16)00063-8. doi: 10.1016/j.euf.2016.02.007. Epub 2016 Oct 17.
Source | Abstract | Full text | Similar articles




Moschini M, Gandaglia G, Suardi N, Fossati N, Cucchiara V, Damiano R, Cantiello F, Shariat SF, Montorsi F, Briganti A.
Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer.
Int J Urol. 2015 Jun;22(6):555-61. doi: 10.1111/iju.12748. Epub 2015 Mar 17.
Source | Abstract | Full text | Similar articles




Narita S, Mitsuzuka K, Tsuchiya N, Koie T, Kawamura S, Ohyama C, Tochigi T, Yamaguchi T, Arai Y, Habuchi T; Michinoku Japan Urological Cancer Study Group.
Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Int J Urol. 2015 Nov;22(11):1029-35. doi: 10.1111/iju.12898. Epub 2015 Aug 20.
Source | Abstract | Full text | Similar articles




Pollard ME, Hobbs AR, Kwon YS, Katsigeorgis M, Lavery HJ, Levinson A, Bernstein AN, Collingwood SA, Hall SJ, Samadi DB, Jazayeri SB.
Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score.
Oncol Res Treat. 2017 Aug 10;40(9). doi: 10.1159/000477545. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW.
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy.
Brachytherapy. 2013 May-Jun;12(3):204-9. doi: 10.1016/j.brachy.2011.12.013. Epub 2012 Jun 5.
Source | Abstract | Full text | Similar articles




Reese AC, Pierorazio PM, Han M, Partin AW.
Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system.
Urology. 2012 Nov;80(5):1075-9. doi: 10.1016/j.urology.2012.07.040. Epub 2012 Sep 18.
Source | Abstract | Full text | Similar articles




Schiffmann J, Wenzel P, Salomon G, Budäus L, Schlomm T, Minner S, Wittmer C, Kraft S, Krech T, Steurer S, Sauter G, Beyer B, Boehm K, Tilki D, Michl U, Huland H, Graefen M, Karakiewicz PI.
Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Urol Oncol. 2015 Jul;33(7):329.e13-9. doi: 10.1016/j.urolonc.2015.04.004. Epub 2015 May 7.
Source | Abstract | Full text | Similar articles




Taneja SS.
Re: The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease.
J Urol. 2014 Aug;192(2):422. doi: 10.1016/j.juro.2014.05.078. Epub 2014 May 14.
Source | Abstract | Full text | Similar articles




Wallner KE.
Commentary on "Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy".
Brachytherapy. 2013 May-Jun;12(3):202. doi: 10.1016/j.brachy.2013.01.001. Epub 2013 Feb 12.
Source | Abstract | Full text | Similar articles




Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF Rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Eur Urol Focus. 2017 Jun 17. pii: S2405-4569(17)30148-7. doi: 10.1016/j.euf.2017.05.011. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Yashi M.
Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer.
Int J Urol. 2015 Jun;22(6):561-2. doi: 10.1111/iju.12764. Epub 2015 Mar 18.
Source | Abstract | Full text | Similar articles





TREATMENT



Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA.
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):693-9. doi: 10.1016/j.ijrobp.2012.06.030. Epub 2012 Jul 25.
Source | Abstract | Full text | Similar articles




Garisto JD, Klotz L.
Active Surveillance for Prostate Cancer: How to Do It Right.
Oncology (Williston Park). 2017 May 15;31(5):333-40, 345.
Source | Abstract | Full text | Similar articles




Masic S, Washington SL 3rd, Carroll PR.
Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?
Curr Opin Urol. 2017 May;27(3):231-237. doi: 10.1097/MOU.0000000000000387.
Source | Abstract | Full text | Similar articles




Nyame YA, Almassi N, Haywood SC, Greene DJ, Ganesan V, Dai C, Zabell J, Reichard C, Arora H, Zampini A, Crane A, Hettel D, Elshafei A, Fareed K, Stein RJ, Berglund RK, Gong M, Jones JS, Klein EA, Stephenson AJ.
Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
J Urol. 2017 Sep;198(3):591-599. doi: 10.1016/j.juro.2017.03.123. Epub 2017 Mar 24.
Source | Abstract | Full text | Similar articles




Zumsteg ZS, Zelefsky MJ.
Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?
Lancet Oncol. 2012 Jun;13(6):e259-69. doi: 10.1016/S1470-2045(12)70084-0.
Source | Abstract | Full text | Similar articles